We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Combining ECG and Blood Tests Reduces Unnecessary Heart Transplant Biopsies

By LabMedica International staff writers
Posted on 07 Oct 2026

Cardiac transplant rejection occurs when a recipient’s immune system attacks a donated heart. More...

Diagnosis currently relies on biopsy, an invasive procedure in which heart muscle tissue is removed and examined for inflammation and other rejection-related changes. To reduce reliance on biopsy, clinicians need accurate, less invasive methods that can help identify patients who may not require tissue sampling. Addressing this need, a new study shows that AI may help detect rejection by combining electrocardiogram data with blood test results.

Researchers at NYU Langone Health developed a multimodal artificial intelligence model that analyzes electrocardiograms (EKGs) alongside two blood biomarkers commonly used to predict rejection risk. EKGs record the heart’s electrical activity using sensors placed on the skin, while the blood biomarkers measure gene activity linked to cellular rejection and fragments of donor DNA in the recipient’s bloodstream.

The team trained AI models using 5,300 EKG readings from 2,357 adult heart transplant recipients. One model used EKG data alone, while another combined EKG readings with the two blood test results. Biopsy records paired with EKG readings from the same patients were used to assess prediction accuracy.

For the combined model, researchers used data from heart transplant recipients treated between 2018 and 2024. Each EKG was matched to a biopsy performed within the previous month. Rejection findings were grouped as no or mild rejection versus moderate or severe rejection, reflecting the fact that treatment changes, such as adjustments to immune-suppressing medications, are typically made for more serious cases.

In a separate test group of 38 male and female heart transplant recipients, the combined model performed better than blood testing alone. It correctly identified 94% of patients who were not experiencing rejection. Compared with blood testing alone, which incorrectly flagged 19 patients as potentially needing a biopsy, the combined model would have spared those patients from the procedure.

The study was published online on September 25 in JHLT Open. The researchers stated that it is the first study to combine these blood biomarkers with EKG readings in a single AI-enabled model and directly compare the analysis with biopsy results. The team plans to test the model in more patients at several transplant centers.

“Our results highlight that electrocardiograms contain an abundance of physiological information that can be used to substantially improve the accuracy of detection and enable earlier diagnosis and treatment for patients with cardiac transplant rejection,” said Lior Jankelson, M.D., Ph.D., associate professor in the Leon H. Charney Division of Cardiology in NYU Grossman School of Medicine’s Department of Medicine and associate professor of biomedical engineering at NYU Tandon School of Engineering.

“Heart transplantation is a major, resource-intensive procedure, and rejection is common but treatable if caught in time. Based on our findings, combining the availability of EKGs with the support of AI may help identify rejection earlier and save more lives,” added Jankelson.

Related Links
NYU Langone Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Urinalysis Solution
UN-9000
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.